Sign Up for a Free Account
  • Updated 03.20.2021
  • Released 03.21.2001
  • Expires For CME 03.20.2024



Historical note and terminology

Cholinesterase inhibitors remain the dominant approach concerning the symptomatic treatment of Alzheimer disease. In 1993, tacrine was the first cholinesterase inhibitor approved by the Food and Drug Administration for use in Alzheimer disease. Following tacrine was the approval of donepezil in 1996 and rivastigmine in 2000. Galantamine (also called galanthamine in some studies) hydrobromide was approved in 2001 by the FDA. A solution preparation is also available for patients who either cannot swallow tablets or prefer liquid medications.

Galantamine was discovered accidentally in the 1950s by a Bulgarian pharmacologist in the bulbs and flowers of wild Caucasian snow drops, Galanthus woronowii (28). Initially, it was used as an agent to reverse the effect of curare in anesthetic practice.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660